You are here: Home » Current Affairs » Coronavirus » News
India, S Africa's proposal for patent waiver on vax gets G7 support: MEA
Ministry of Defence allocates Rs 500 cr for designing innovative products
Business Standard

Zydus Cadila may soon seek emergency use authorisation for Covid-19 vaccine

This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator

Topics
Zydus Cadila | Coronavirus Vaccine | Lockdown

Sohini Das  |  Mumbai 



Photo: Shutterstock
This could also be India’s first vaccine for children aged 12 years and above as the company has conducted trials on the age group | Photo: Shutterstock

may soon seek emergency use authorization (EUA) for its DNA-plasmid technology-based Covid-19 vaccine from India’s drug regulator. If approved, this would be the first DNA-plasmid vaccine in the world.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Sun, June 13 2021. 22:28 IST

RECOMMENDED FOR YOU